Jan 6, 2009 - Pfizer Inc announced today that the U.S. PTO has issued a “Notice of Allowance” accepting the company's application to correct the technical defect in the ˜995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor. The company noted that certain formalities must be completed before the reissue patent will be granted. The reissued patent will have the same force and effect as the original ˜995 patent and the same June 2011 expiration date (including the six-month pediatric exclusivity period).
The details can be read here.
No comments:
Post a Comment